List of Excipients in Branded Drug GLATIRAMER ACETATE

Generic Drugs Containing GLATIRAMER ACETATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	glatiramer acetate	0378-6960	MANNITOL
Mylan Pharmaceuticals Inc	glatiramer acetate	0378-6960	WATER
Mylan Pharmaceuticals Inc	glatiramer	0378-6961	MANNITOL
UPSHER-SMITH LABORATORIES LLC	glatiramer acetate injection	0832-6084	MANNITOL
UPSHER-SMITH LABORATORIES LLC	glatiramer acetate injection	0832-6084	WATER

What are the Most Frequently-Used Excipients in GLATIRAMER ACETATE?

# Of NDCs	Excipient
9	MANNITOL
5	WATER

Glatiramer Acetate Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Glatiramer acetate is a synthetic mixture of polypeptides used in multiple sclerosis, marketed primarily as Copaxone and generic glatiramer acetate products. Its commercial opportunity is concentrated in formulation control, injectable manufacturing, device compatibility, supply security, and differentiated administration rather than in conventional excipient substitution. The established formulation uses mannitol as the principal excipient, with water for injection and pH control. Generic competition has reduced the value of the active ingredient franchise, but technical barriers remain in peptide-mixture characterization, syringe performance, particulate control, and batch-to-batch comparability.

What excipients are used in glatiramer acetate injections?

The principal excipient in marketed glatiramer acetate injection is mannitol.

Product	Strength	Active ingredient per mL	Principal excipient	Administration
Copaxone	20 mg/mL	20 mg glatiramer acetate	40 mg mannitol	Subcutaneous, once daily
Copaxone	40 mg/mL	40 mg glatiramer acetate	40 mg mannitol	Subcutaneous, three times weekly
Glatopa	20 mg/mL	20 mg glatiramer acetate	Mannitol	Subcutaneous, once daily
Glatopa	40 mg/mL	40 mg glatiramer acetate	Mannitol	Subcutaneous, three times weekly

The products are supplied as sterile, preservative-free solutions for subcutaneous injection. The FDA labeling for Copaxone identifies mannitol and water for injection as formulation components and specifies storage at 2°C to 8°C. The product must not be frozen and should be protected from light [1].

Mannitol has several functional roles:

• It contributes isotonicity.
• It supports solution robustness.
• It is widely available in pharmaceutical and parenteral grades.
• It has an established regulatory history in injectable products.
• It avoids the immunogenic and preservative concerns associated with more complex excipient systems.

The formulation is unusually simple for a chronic injectable therapy. That simplicity limits the opportunity to create value through a new excipient combination, but it increases the commercial importance of raw-material quality, sterile processing, container closure, and analytical control.

Why is mannitol strategically important in glatiramer acetate?

Mannitol is the key formulation lever because changing its concentration can affect osmolality, injection tolerability, peptide behavior, and comparability to the reference product.

A supplier or contract manufacturer can differentiate through:

1. Low-endotoxin mannitol supply.
2. Tight control of bioburden and particulate matter.
3. Consistent particle-size and solution-quality specifications.
4. Validated compatibility with the glatiramer acetate peptide mixture.
5. Dual-source or regional supply arrangements.
6. Documentation packages supporting ANDA, EU generic, and other regulatory filings.

The active ingredient is not a single defined peptide. Glatiramer acetate is a heterogeneous mixture of synthetic polypeptides containing glutamic acid, lysine, alanine, and tyrosine residues in a specified compositional range. The FDA has treated the product as a complex generic drug rather than as a conventional small-molecule solution [2].

That distinction matters. A manufacturer cannot assume that an apparently minor change in mannitol grade, pH, osmolality, container material, or filling process will have no impact. The product must be assessed through a broader comparability package covering chemical composition, molecular-weight distribution, peptide fingerprints, charge characteristics, impurities, potency, and immunological activity.

What excipient changes are commercially feasible?

The strongest near-term opportunity is optimization within the established mannitol-based formulation rather than replacement of mannitol.

Mannitol concentration optimization

A different mannitol concentration could support:

• Reduced injection-site discomfort.
• Improved osmolality control.
• Better stability under transport stress.
• Lower crystallization or precipitation risk.
• Improved compatibility with autoinjectors.

The commercial value depends on whether the change produces a clinically meaningful benefit or enables a regulatory pathway that remains acceptable to the relevant authority. An excipient change that requires a new clinical program would generally be unattractive for a mature, price-competitive product.

Alternative tonicity agents

Potential alternatives include sodium chloride, sorbitol, sucrose, and other established parenteral excipients. These options are technically plausible but commercially constrained.

Excipient option	Potential benefit	Principal risk
Mannitol	Established reference formulation; strong supply base	Limited differentiation
Sodium chloride	Familiar injectable tonicity agent	May affect peptide behavior and injection tolerability
Sorbitol	Liquid-compatible polyol and tonicity agent	Stability, viscosity, and regulatory comparability questions
Sucrose	Stabilization potential	May alter solution properties and analytical comparability
Trehalose	Protein and peptide stabilization history	Higher regulatory and cost burden; limited need in current product
Amino-acid excipients	Potential peptide interaction control	Complex interaction profile and additional characterization

Alternative excipients are more commercially attractive for a new formulation, depot product, or device-led line extension than for a standard generic injection. The main barrier is not excipient availability. It is demonstrating that the change does not alter the product’s biological and immunological profile.

Buffer systems and pH control

The product is formulated within a mildly acidic-to-neutral pH range. A buffer system could improve pH control during storage, but it could also change peptide conformation, aggregation, adsorption, and injection tolerability.

The business case for a buffer is strongest where it solves a documented manufacturing or shelf-life problem. A buffer added solely for formulation novelty is unlikely to justify the additional regulatory and analytical burden.

Preservatives

Preservative-free single-dose presentation is an established characteristic of glatiramer acetate products. A multidose product with a preservative could reduce packaging cost, but it would introduce local tolerability, immunogenicity, container-closure, and regulatory issues.

A preservative strategy is therefore a weak opportunity unless paired with a clearly differentiated multidose device or a major reduction in administration burden.

What formulation patents protect glatiramer acetate?

The original composition and manufacturing patent estate for glatiramer acetate has largely matured, while later protection focused on dosing schedules, formulations, and commercial presentation.

Protection area	Commercial relevance	Current strategic position
Original glatiramer acetate composition	Defined the active polypeptide mixture	Core patents expired or reached the end of their effective term in the 2010s
Manufacturing and composition controls	Can affect generic comparability	Process know-how remains commercially important even where patent protection has weakened
20 mg daily regimen	Supported the original Copaxone franchise	Generic competition is established
40 mg three-times-weekly regimen	Extended product convenience and lifecycle value	Later patents created a higher barrier to entry, but generic entry has occurred
Device and packaging	Supports administration and differentiation	Product-specific device rights and trade secrets may remain relevant
Analytical methods	May protect characterization and release strategy	Often maintained as know-how rather than disclosed formulation IP

Teva’s later patent strategy concentrated on the 40 mg three-times-weekly regimen and related lifecycle protection. U.S. litigation involving generic manufacturers challenged patents associated with that formulation and dosing schedule. The commercial result was a gradual erosion of Copaxone sales as generic products entered the market.

Patent status must be checked against the current FDA Orange Book and individual patent records because listings, pediatric extensions, terminal disclaimers, and litigation outcomes can change the effective risk profile [3,4]. The central practical point is that a new excipient supplier should not assume that the absence of a broad composition patent eliminates freedom-to-operate issues. Manufacturing processes, device interfaces, formulation-specific claims, and confidential know-how can still affect a launch.

When did glatiramer acetate lose exclusivity?

Glatiramer acetate lost effective market exclusivity in stages rather than on one date.

Milestone	Approximate timing	Commercial effect
Original Copaxone composition protection matured	Mid-2010s	Opened the principal pathway for generic development
First FDA-approved generic glatiramer acetate	2017	Established ANDA-based competition
Generic 40 mg three-times-weekly products	Late 2010s onward	Pressured the higher-value lifecycle formulation
Continued regional generic expansion	2020s	Reduced branded volume and increased price competition

The FDA approved Sandoz’s Glatopa 20 mg in 2017 as the first generic version of Copaxone 20 mg. FDA later approved glatiramer acetate 40 mg products, including products associated with Mylan and Sandoz, expanding competition against Copaxone 40 mg [5,6].

Glatiramer acetate is not a conventional biologic subject to the biosimilar pathway. It is generally pursued through an abbreviated generic drug application because the reference product is regulated as a complex synthetic drug product. This makes ANDA strategy, not biosimilar interchangeability, the principal competitive framework.

What FDA regulatory issues affect excipient strategy?

The FDA’s central concern is whether the proposed product is the same as the reference product in all clinically relevant respects. For glatiramer acetate, that assessment extends beyond standard assay and impurity testing.

Key regulatory areas include:

Active-mixture characterization

The sponsor must characterize the heterogeneous polypeptide mixture using multiple analytical methods. Relevant attributes include:

• Amino-acid composition.
• Molecular-weight distribution.
• Peptide sequence or sequence-related profiles.
• Charge distribution.
• Hydrophobicity.
• Aggregation and degradation.
• Functional and immunological activity.

Excipient equivalence

The formulation should use the same excipient strategy where possible. If the sponsor changes mannitol source, concentration, buffer, or other inactive ingredients, it must demonstrate that the change does not affect product quality, safety, performance, or immunogenicity.

Container closure

The syringe, needle, stopper, barrel, lubricant, and secondary packaging can influence:

• Extractables and leachables.
• Adsorption of peptide material.
• Silicone-oil levels.
• Delivered volume.
• Needle force.
• Break-loose and glide force.
• Subvisible particle counts.

The container closure is therefore part of the formulation and device strategy, even when the liquid composition is unchanged.

Stability and shipping

The labeled cold-chain requirement creates opportunity for improved stability programs. A product that supports wider temperature excursions could reduce distribution cost, but the sponsor must establish this through real-time and accelerated stability data. A temperature-tolerant formulation would have more commercial value than a minor excipient substitution.

What commercial opportunities exist for excipient suppliers?

The largest addressable opportunities are enabling technologies rather than high-margin novel excipients.

High-purity mannitol supply

Mannitol suppliers can compete on:

• Parenteral-grade quality.
• Low endotoxin.
• Global regulatory documentation.
• Lot consistency.
• Security of supply.
• Regional inventory.
• Support for process validation.

A dual-source strategy is commercially valuable because glatiramer acetate is a chronic-use injectable with recurring demand and limited tolerance for supply interruptions.

Custom excipient specifications

Manufacturers may require tighter specifications than pharmacopoeial standards for:

• Endotoxin.
• Residual solvents.
• Bioburden.
• Metal contaminants.
• Particulates.
• Peroxide content.
• Moisture.
• Microbial limits.

The supplier that can link these specifications to peptide stability and finished-product performance has greater negotiating leverage than a commodity supplier.

Syringe and device compatibility

Excipient suppliers can partner with prefilled-syringe and autoinjector manufacturers to test:

• Surface interactions.
• Silicone oil migration.
• Needle force.
• Injection time.
• Dose delivery.
• Product hold-up volume.
• Peptide adsorption.

This opportunity is commercially stronger than a simple new excipient claim because it connects formulation quality with patient usability and device performance.

Analytical and comparability services

Specialized laboratories can support generic and regional manufacturers with:

• Peptide fingerprinting.
• Molecular-weight profiling.
• Charge-variant analysis.
• Immunoreactivity testing.
• Particulate characterization.
• Stability-indicating methods.
• Container-closure studies.

These services create recurring revenue during development, registration, post-approval changes, and supplier qualification.

Which companies are challenging the glatiramer acetate franchise?

The principal competitive groups are Teva, Sandoz, Viatris, and other regional generic manufacturers.

Company	Product or role	Competitive significance
Teva	Copaxone	Originator and historical market leader
Sandoz	Glatopa	First major FDA-approved generic entrant
Viatris/Mylan	Generic glatiramer acetate	Expanded U.S. generic competition
Regional manufacturers	National-market generic products	Increase price and supply competition outside the U.S.

Competition is based on more than active pharmaceutical ingredient cost. Suppliers must manage sterile fill-finish capacity, cold-chain distribution, prefilled syringes, device economics, regulatory documentation, and physician or payer acceptance.

What generic launch scenarios exist for glatiramer acetate?

Three launch scenarios are commercially relevant.

Commodity generic launch

The sponsor uses the established mannitol formulation, a standard prefilled syringe, and a conventional distribution model. This is the lowest-risk strategy but produces the greatest price pressure.

Device-led differentiated launch

The product uses an autoinjector, improved needle system, lower injection force, or enhanced adherence support. The excipient remains conventional, while value is created through administration and patient experience.

Formulation-led lifecycle product

The sponsor develops improved stability, reduced injection-site reactions, or a new administration schedule. This strategy has a higher development burden and may require a new drug application or a more complex regulatory submission. It is the highest-value but highest-risk path.

The most practical opportunity is a combination of the first and second scenarios: a regulatory-conservative liquid formulation paired with a differentiated device and resilient supply chain.

How strong is the glatiramer acetate patent estate?

The estate is weak for broad composition protection and stronger for selected implementation details.

Broad patent strength is limited because:

• The original active ingredient has been commercially available for decades.
• Generic products have obtained FDA approval.
• Core composition protection has largely matured.
• Multiple manufacturers have established production routes.

Residual strength may remain in:

• Specific manufacturing conditions.
• Defined compositional windows.
• Dosing regimens.
• Device configurations.
• Packaging systems.
• Analytical release methods.
• Confidential process knowledge.

For an excipient company, the principal legal risk is usually indirect. A new excipient or formulation may create freedom-to-operate issues if it is claimed in a later formulation patent, but the more common risk is regulatory failure caused by inadequate comparability data.

What is the revenue exposure from Copaxone generic competition?

Copaxone was historically one of Teva’s largest products, with annual sales reaching several billion dollars before generic erosion. Teva’s annual reports describe continued sales declines as generic glatiramer acetate products entered the U.S. market and pricing pressure increased [7].

The revenue opportunity has shifted from originator margin capture to supply-chain participation:

• Active ingredient production.
• Mannitol and other injectable excipients.
• Prefilled syringes.
• Autoinjectors.
• Sterile fill-finish.
• Analytical comparability.
• Cold-chain logistics.
• Regional licensing and distribution.

This market remains commercially relevant because multiple sclerosis treatment is chronic and product demand is recurring. The addressable revenue is more fragmented than during Copaxone’s exclusivity period.

What geographic opportunities exist for glatiramer acetate excipients?

The United States is the most mature generic market. Europe has a broad generic and national tender environment, while Latin America, the Middle East, and parts of Asia offer opportunities tied to local registration, pricing, and manufacturing requirements.

A regional strategy should account for:

• Different reference-product requirements.
• National substitution rules.
• Tender-based purchasing.
• Local manufacturing incentives.
• Cold-chain infrastructure.
• Device registration.
• Pharmacovigilance obligations.
• Variations in accepted comparability packages.

A supplier with regulatory files for the United States, European Union, and major emerging markets can reduce customer qualification time. Local inventory and technical support may be more valuable than a marginally lower excipient price.

Key Takeaways

• Mannitol is the principal excipient in marketed glatiramer acetate injections.
• The strongest formulation strategy is usually to preserve the established mannitol-based design.
• Excipient substitution is technically possible but creates comparability, immunogenicity, and regulatory risk.
• The active ingredient is a heterogeneous synthetic polypeptide mixture, making analytical control central to product approval.
• Glatiramer acetate competes through the ANDA generic pathway rather than the biosimilar pathway.
• Core composition protection has largely matured, while formulation, dosing, device, and process rights require current review.
• Commercial opportunities are strongest in pharmaceutical-grade mannitol, sterile manufacturing, syringe compatibility, analytical services, and device-led differentiation.
• A standard generic launch faces severe price competition. A device-supported launch offers a stronger margin opportunity without requiring a novel excipient.
• Stability improvement and supply security are more commercially credible than a purely cosmetic excipient change.

FAQs About Glatiramer Acetate Excipient Commercialization

Can sodium chloride replace mannitol in glatiramer acetate?

It can be evaluated technically, but substitution would require extensive comparability work covering osmolality, peptide-mixture characteristics, stability, injection tolerability, and immunological activity. It is not a low-burden generic formulation change.

Is glatiramer acetate a biologic for biosimilar purposes?

No. Glatiramer acetate is generally regulated as a complex synthetic drug product and has been approved through the abbreviated generic pathway. Its complexity affects analytical comparability but does not place it within the standard biosimilar framework.

Does mannitol have patent protection in glatiramer acetate products?

Mannitol itself is a long-established excipient and is not the principal source of exclusivity. Patent risk may arise from a specific concentration, formulation, process, device, or use claim associated with a finished product.

Can a preservative improve the economics of glatiramer acetate?

A preservative could support multidose packaging, but it would introduce tolerability, immunogenicity, microbiological, and regulatory issues. The economics are more attractive when paired with a validated multidose device and a clear reduction in administration burden.

What is the best entry point for an excipient supplier?

The most defensible entry point is a high-quality, low-endotoxin mannitol platform supported by stability data, container-closure compatibility, regulatory documentation, and dual-source manufacturing capacity.

References

1. U.S. Food and Drug Administration. (2024). Copaxone (glatiramer acetate injection) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2017). Draft guidance on glatiramer acetate. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov
5. U.S. Food and Drug Administration. (2017). FDA approves first generic version of widely used multiple sclerosis drug. https://www.fda.gov
6. U.S. Food and Drug Administration. (2020). Drugs@FDA: Glatiramer acetate injection. https://www.accessdata.fda.gov/scripts/cder/daf/
7. Teva Pharmaceutical Industries Ltd. (2024). Annual report 2023. https://ir.tevapharm.com